Ownership and insider activity for Inventiva S.A. (IVA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases.
Price
| Price | $3.79 |
| Market Cap | $197M |
| Exchange | NASDAQ |
| Country | FR |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.9M | $59.1M | $56.7M | $35.8M | $105.7M | $86.6M | $86.7M | $26.9M | $96.6M | $99.3M |
| Short-term Investments | 0 | 0 | 0 | 0 | $7.3M | 0 | $1.0M | $70000 | 0 | 0 |
| Receivables | $4.5M | $6.9M | $13.3M | $643000 | $48000 | $11.6M | $279000 | $15.7M | $12.2M | $9.1M |
| Inventory | $471879 | $473129 | $410000 | $387000 | $320000 | $392000 | $373000 | $417000 | 0 | 0 |
| Total Current Assets | $41.2M | $67.2M | $71.6M | $48.9M | $133.0M | $115.6M | $106.4M | $48.2M | $111.5M | $243.8M |
| Property, Plant & Equipment | $5.0M | $4.5M | $4.3M | $3.7M | $3.3M | $3.2M | $7.4M | $9.1M | $5.0M | $3.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $2.1M | $1.8M | $1.5M | $1.2M | $935000 | $770000 | $568000 | $541000 | $48000 | $181921 |
| Total Assets | $48.9M | $74.4M | $79.8M | $57.0M | $138.9M | $122.0M | $116.0M | $69.6M | $119.0M | $248.9M |
| Accounts Payable | $4.4M | $5.4M | $8.4M | $7.5M | $6.9M | $14.6M | $19.4M | $37.7M | $32.9M | $26.0M |
| Short-term Debt | $145746 | $307000 | $2.1M | $77000 | $16000 | $1.2M | $4.6M | $3.0M | $3.3M | $30.3M |
| Total Current Liabilities | $8.6M | $8.8M | $15.1M | $13.9M | $13.9M | $22.9M | $30.7M | $50.2M | $120.7M | $77.3M |
| Long-term Debt | $481858 | $220000 | $74000 | 0 | $10.0M | $8.7M | $25.4M | $27.9M | $46.3M | $24.8M |
| Total Liabilities | $13.1M | $10.4M | $18.2M | $15.6M | $27.7M | $33.1M | $70.5M | $101.6M | $225.6M | $277.9M |
| Retained Earnings | -$7.0M | -$17.2M | -$33.6M | -$30.2M | -$33.6M | -$49.6M | -$54.3M | -$110.4M | -$184.2M | -$354.1M |
| Total Equity | $35.7M | $64.0M | $61.6M | $41.4M | $111.2M | $88.9M | $45.5M | -$32.0M | -$106.6M | -$29.0M |
| Total Debt | $627604 | $482066 | $2.2M | $114000 | $10.1M | $10.1M | $34.5M | $37.5M | $54.3M | $59.4M |
| Net Debt | -$24.2M | -$58.6M | -$54.5M | -$35.7M | -$103.0M | -$76.4M | -$53.3M | $10.1M | -$42.2M | -$39.9M |
| Working Capital | $32.6M | $58.4M | $56.6M | $35.0M | $119.1M | $92.7M | $75.7M | -$2.0M | -$9.2M | $166.5M |
Financial Health
| Debt / Equity | -2.10 |
| Current Ratio | 3.16 |
Profitability
| Return on Equity | 1870.38% |
| Return on Invested Capital | -66.18% |
| Return on Assets | -141.93% |
| Gross Margin | 35.07% |
| Operating Margin | -3037.30% |
| Net Margin | -7899.58% |
Related companies: AVTX · CRBU · ENTA · EPRX · GNFT · IVVD · NAUT
Explore sector: Healthcare · Biotechnology
More sections of IVA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks